CA2150554A1 - Cyclodextrin and polymer based drug delivery system - Google Patents
Cyclodextrin and polymer based drug delivery systemInfo
- Publication number
- CA2150554A1 CA2150554A1 CA002150554A CA2150554A CA2150554A1 CA 2150554 A1 CA2150554 A1 CA 2150554A1 CA 002150554 A CA002150554 A CA 002150554A CA 2150554 A CA2150554 A CA 2150554A CA 2150554 A1 CA2150554 A1 CA 2150554A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- beta
- defined above
- alkyl
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/984,445 | 1992-12-02 | ||
| US07/984,445 US5332582A (en) | 1990-06-12 | 1992-12-02 | Stabilization of aminosteroids for topical ophthalmic and other applications |
| US15516793A | 1993-11-19 | 1993-11-19 | |
| US08/155,167 | 1993-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2150554A1 true CA2150554A1 (en) | 1994-06-09 |
Family
ID=26852057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002150554A Abandoned CA2150554A1 (en) | 1992-12-02 | 1993-12-01 | Cyclodextrin and polymer based drug delivery system |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0674528A4 (zh) |
| JP (1) | JPH08503951A (zh) |
| CN (1) | CN1103316A (zh) |
| AU (1) | AU672862B2 (zh) |
| CA (1) | CA2150554A1 (zh) |
| WO (1) | WO1994012217A1 (zh) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW434023B (en) * | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| JP3940209B2 (ja) | 1996-11-14 | 2007-07-04 | 株式会社資生堂 | 可溶化化粧料 |
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6656456B2 (en) | 1998-11-23 | 2003-12-02 | The Procter & Gamble Company | Skin deodorizing compositions |
| WO2000030599A1 (en) * | 1998-11-23 | 2000-06-02 | The Procter & Gamble Company | Skin deodorizing and sanitizing compositions |
| CA2373237A1 (en) * | 2000-03-10 | 2001-09-20 | Insite Vision Incorporated | Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| SI1278549T1 (sl) | 2000-05-02 | 2009-04-30 | Theravance Inc | Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik |
| US6828299B2 (en) | 2000-06-22 | 2004-12-07 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| ES2302733T3 (es) | 2000-06-22 | 2008-08-01 | Theravance, Inc. | Derivados carboxi-sacaridos de glucopeptido. |
| US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| AU2001288120A1 (en) * | 2000-09-26 | 2002-04-08 | Kyorin Pharmaceutical Co. Ltd. | Liquid prednisolone sodium phosphate preparation |
| CA2445606A1 (en) * | 2001-05-11 | 2002-11-21 | Pacific Pharmaceuticals Limited | Taste masking pharmaceutical composition |
| WO2004091630A1 (ja) * | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | 眼に適用する疾患治療剤 |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| WO2006040839A1 (ja) * | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | 眼疾患処置用点眼剤及びキット |
| JP2007177149A (ja) * | 2005-12-28 | 2007-07-12 | Shield Lab:Kk | チオクト酸又はジヒドロリポ酸と分岐鎖シクロデキストリンとの包接化合物 |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| EP2234614B1 (de) | 2007-12-21 | 2012-10-17 | AOP Orphan Pharmaceuticals AG | Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamen beta-adrenorezeptor antagonisten |
| US10980818B2 (en) | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
| US20150258120A1 (en) | 2012-11-08 | 2015-09-17 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| US20150374832A1 (en) * | 2013-02-12 | 2015-12-31 | Ys Pharm Tech | Epinephrine formulations for medicinal products |
| JP6379183B2 (ja) | 2013-05-03 | 2018-08-22 | クリアサイド バイオメディカル，インコーポレイテッド | 眼球注射の装置および方法 |
| US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
| CN103990137A (zh) * | 2014-04-30 | 2014-08-20 | 福建融和药业有限公司 | 一种粘膜粘附性聚合物眼用药物的缓释剂 |
| US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
| JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル，インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
| CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
| CN109136177B (zh) * | 2018-08-03 | 2021-09-17 | 湖南大学 | 一种地塞米松缓释体系以及一种成骨分化诱导液和应用 |
| RU2740287C1 (ru) * | 2019-08-30 | 2021-01-12 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | 3д-матриксная структура для доставки лекарственных препаратов |
| CN115380899A (zh) * | 2022-08-30 | 2022-11-25 | 陕西科技大学 | 一种凝胶型腐植酸缓释农药及其制备方法 |
| WO2024097388A1 (en) * | 2022-11-03 | 2024-05-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for monitoring fatty acid metabolism |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| NZ225045A (en) * | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| IE63392B1 (en) * | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| ES2062359T3 (es) * | 1989-05-24 | 1994-12-16 | Innovet Inc | Un procedimiento de preparacion de una composicion anestesica o hipnotica esteroidal hipoalergenica. |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
-
1993
- 1993-12-01 WO PCT/US1993/011651 patent/WO1994012217A1/en not_active Application Discontinuation
- 1993-12-01 CA CA002150554A patent/CA2150554A1/en not_active Abandoned
- 1993-12-01 JP JP6513478A patent/JPH08503951A/ja active Pending
- 1993-12-01 AU AU56841/94A patent/AU672862B2/en not_active Ceased
- 1993-12-01 EP EP94902482A patent/EP0674528A4/en not_active Withdrawn
- 1993-12-02 CN CN93120402A patent/CN1103316A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08503951A (ja) | 1996-04-30 |
| AU5684194A (en) | 1994-06-22 |
| EP0674528A4 (en) | 1996-06-26 |
| EP0674528A1 (en) | 1995-10-04 |
| AU672862B2 (en) | 1996-10-17 |
| CN1103316A (zh) | 1995-06-07 |
| WO1994012217A1 (en) | 1994-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2150554A1 (en) | Cyclodextrin and polymer based drug delivery system | |
| US5538721A (en) | Stabilization of aminosteroids for topical ophthalmic and other applications | |
| Loftsson et al. | Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye | |
| Loftssona et al. | Cyclodextrins in ophthalmic drug delivery | |
| EP0794783B1 (en) | Cyclodextrins as suspending agents for pharmaceutical suspensions | |
| US8633172B2 (en) | Cyclodextrin nanotechnology for ophthalmic drug delivery | |
| Loftsson et al. | Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye | |
| EP0730443B1 (en) | Suspension of loteprednol etabonate | |
| US20040152664A1 (en) | Prednisolone compositions | |
| JPH06239748A (ja) | セチリジン含有抗アレルギー点眼点鼻用組成物 | |
| US4642305A (en) | Eye drops composition | |
| CN102724965B (zh) | 含羧乙烯基聚合物的纳米颗粒混悬液 | |
| EP1567125A2 (en) | Pharmaceutical compositions suitable for the treatment of ophthalmic diseases | |
| US20050059615A1 (en) | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | |
| Patil et al. | Advances in progesterone delivery systems: Still work in progress? | |
| US5977180A (en) | Anandamide analog compositions and method of treating intraocular hypertension using same | |
| WO2007013590A1 (ja) | 固形組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム | |
| JP5087242B2 (ja) | ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム | |
| JP3147076B2 (ja) | ロテプレドノール エタボネート水性懸濁液 | |
| CN115837027A (zh) | 一种眼用地塞米松药物组合物 | |
| TW201932110A (zh) | 供每日一次用之苯並咪唑化合物的眼用組成物 | |
| Bary | Considerations in the use of cyclodextrins in the reformation of ophthalmic suspensions as solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |